Patient n/gender	Type of Myeloproliferative disease	First thrombosis	Second thrombosis	Additional prothrombotic risk factor/ JAK 2 status	Type of Heparin	Anticoagulant after heparin withdrawal	Days elapsing between 1st and 2nd thrombosis	Platelets at 1st thrombosis, 109/l	Platelet nadir, !109/l	Total 4 T’s score	H/PF4 Ab IgG OD
1/F	ET	Coronary artery disease	ictus	None/ V617F	LMWH	Lepirudin/oral anticoagulants	14	456	90	7	> 2
2/F	ET	Mesenteric thrombosis	ictus	F V Leiden/ V617F	UFH	Lepirudin/oral anticoagulants	12	729	300	8	> 2
3/F	ET	Coronary artery disease	Arterial limb ischemia	None/ V617F	LMWH	Lepirudin/oral anticoagulants	10	859	268	8	> 2
4/M	ET	Portal vein thrombosis	Sinus vein thrombosis	none /V617F	LMWH	Lepirudin/oral anticoagulants	12	426	87	8	> 2
5/M	ET	Portal vein thrombosis	Pulmonary embolism	none /V617F	LMWH	Lepirudin/oral anticoagulants	12	830	422	7	> 2
6/F	ET	Coronary artery disease	Central vein thrombosis	None/ V617F	UFH	Lepirudin/oral anticoagulants	15	236	64	7	> 2
7/M	ET	Coronary artery disease	Central vein thrombosis	Prothrombin G20210A mutations/ V617F	LMWH	Lepirudin/oral anticoagulants	14	657	275	7	> 2
8/F	ET	DVT	Splacnic vein thrombosis	None/ V617F	UFH	Fondaparinus	15	67	12	8	> 2
9/F	ET	Surgery prophylaxis	Splacnic vein thrombosis	None/ V617F	LMWH	oral anticoagulants	8	230	87	7	o.10
10/M	ET	DVT	Splacnic vein thrombosis	None/ V617F	LMWH	Fondaparinus	12	342	67	7	> 2
11/M	ET	DVT	Ictus	None/negative	LMWH	Lepirudin/oral anticoagulants	15	360	78	7	> 2
12/F	ET	Surgery prophylaxis	Arterial limb ischemia	None/negative	LMWH	Lepirudin/oral anticoagulants	16	398	58	7	> 2

Biological and Clinical Features of 12 patients affected by Essential Trombocytopenia (ET) who presented thrombotic complications during heparin treatment DVT. Deep vein thrombosis, LMWH. Low molecular weight heparin. UFH.: Unfractioned heparin.